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Abstract
Objective: Intravenous iron is widely used to treat iron deficiency in day-care units. Ferric carboxymaltose (FCM) allows
administration of larger iron doses than iron sucrose (IS) in each infusion (1000 mg vs. 200 mg). As FCM reduces the number
of infusions required but is more expensive, we performed a cost-minimization analysis to compare the cost impact of the
two drugs.
Materials and Methods: The number of infusions and the iron dose of 111 consecutive patients who received intravenous
iron at a gastrointestinal diseases day-care unit from 8/2007 to 7/2008 were retrospectively obtained. Costs of intravenous
iron drugs were obtained from the Spanish regulatory agencies. The accounting department of the Hospital determined
hospital direct and indirect costs for outpatient iron infusion. Non-hospital direct costs were calculated on the basis of
patient interviews. In the pharmacoeconomic model, base case mean costs per patient were calculated for administering
1000 mg of iron per infusion using FCM or 200 mg using IS. Sensitivity analysis and Monte Carlo simulation were
performed.
Results: Under baseline assumptions, the estimated cost of iron infusion per patient and year was J304 for IS and J274 for
FCM, a difference of J30 in favour of FCM. Adding non-hospital direct costs to the model increased the difference to J67
(J354 for IS vs. J287 for FCM). A Monte Carlo simulation taking into account non-hospital direct costs favoured the use of
FCM in 97% of simulations.
Conclusion: In this pharmacoeconomic analysis, FCM infusion reduced the costs of iron infusion at a gastrointestinal day-
care unit.
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Introduction
Patients with digestive conditions such as chronic liver disease or
inflammatory bowel disease frequently suffer from chronic iron
losses that require large doses of supplemental iron. In these
patients, oral iron administration is often not feasible or sufficient
because intestinal absorption and digestive tolerance of iron salts
are poor [1]. By contrast, intravenous (i.v.) iron is usually well
tolerated and allows administration of larger iron doses [2]. Many
studies have shown that i.v. iron is more efficacious and better
tolerated than oral iron supplementation [1;3–8]. In addition, in
patients with inflammatory bowel disease it remains unclear
whether large oral iron doses may induce disease flares or may
even increase cancer risk [9].
In the past, iron dextran formulations carried a significant risk
of anaphylaxis. For this reason, new formulations such as iron
sucrose (IS) and, later, ferric carboxymaltose (FCM) were
developed [10]. These compounds have shown an excellent safety
profile and IS was the preferred drug in most hospitals until FCM
became available. Although both compounds allow administration
of much larger daily doses than their oral counterparts, FCM
allows the administration of up to 1000 mg of iron in a single
infusion, while IS administration is restricted to a maximum of
200 mg per day [11]. Although FCM is more expensive than other
i.v. iron preparations, the ability to administer higher doses has a
clear advantage for both patients and day care units, as fewer
hospital visits and vein punctures are required [12–13]. It is
important, however, to determine the comparative total costs of
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both strategies from the hospital and societal perspectives in order
to determine which infusion strategy is preferable.
The aim of this study was to compare the cost implications of
using i.v. FCM versus IS – at present the most used i.v. therapy –
for treating iron deficiency in a specialized day-care unit devoted
to digestive diseases, using a cost-minimization analysis.
Patients and Methods
The records of 111 consecutive patients receiving i.v. iron at the
gastrointestinal diseases day-care unit of the Hospital de Sabadell,
Barcelona, Spain, from August 2007 to July 2008 were retrospec-
tively reviewed. Data on the number of infusions and the amount
of iron administered per patient were collected. The full
description of the series of patients has been published elsewhere
[14]. Costs of drugs were obtained from the prices approved by the
Spanish Agency for the Regulation of Drugs and Healthcare
Products [15]. All personnel and indirect costs were obtained from
the accounting department of the Hospital of Sabadell. The
Hospital’s accounting department determines the direct and
indirect costs for outpatient iron infusions by using a full-cost
model for assigning costs to each process. This model attributes all
corresponding organizational costs to any process or product
whose cost one intends to measure. The cost of the product or the
process includes direct and indirect costs. Direct costs include the
needs for medical material, personnel and diagnostic procedures.
In this case cost of personnel was calculated including all the staff
working part or full time in the day-care unit, and included
nursing and auxiliary personnel plus part-time medical surveil-
lance. Indirect costs include the fraction of the common hospital
costs imputable to a process and include (among other things)
administrative costs, structural costs, and maintenance and
cleaning services. This is performed by dividing the hospital into
different processes and sub-processes with their corresponding
direct and indirect cost assignation. In addition to direct and
indirect costs, non-hospital direct costs were calculated by asking a
consecutive unselected series of 605 patients –297 female, mean
age 50625 years, of whom 161 were actively working – about the
costs associated with travelling to the hospital and missed working
hours. Costs were measured in J for the year 2009. Costs were not
discounted due to the short time frame of analysis.
A pharmacoeconomical evaluation by using cost minimization
analysis was performed from hospital and societal perspectives, the
latter including non-hospital direct costs. Cost-minimization is a
tool used in pharmacoeconomics and is applied when comparing
multiple drugs of equal efficacy and equal tolerability. Theoretical
base case total costs per patient were calculated using the
individual patients’ data for two scenarios: 1) administering the
amount of iron required for each patient with 1000 mg of iron per
infusion using FCM or 2) administering 200 mg of iron per
infusion using IS. For the FCM infusion, the dose was rounded to
the next 1000 mg dose. Thus, a patient who received a total dose
of 800 mg of iron was assumed to receive four doses of IS or one
1000 mg infusion of FCM and a patient receiving 1400 mg of IS
was assumed to receive two 1000 mg infusions of i.v. iron. Primary
outcome measure was the cost of infusion per patient in one year.
This parameter was calculated by adding: 1) the cost of
intravenous iron, 2) direct hospital costs (personnel, infusion
material) and 3) indirect hospital costs (the general functioning
costs) and 4) direct non-hospital costs (travel, time off work for the
patient and – if applicable – the accompanying person).
Calculations were performed using Microsoft Excel XPTM.
One-way and two-way sensitivity analyses were performed by
changing baseline estimates for costs within a range of potentially
reasonable values and evaluating whether these changes modify
the conclusions reached using baseline estimates for costs. Finally,
probabilistic sensitivity analysis was performed using Monte Carlo
simulation for Microsoft Excel XPTM. Monte Carlo simulations
are a class of computational algorithms that rely on repeated
random sampling to compute their results. The model assigns
random values under a predetermined distribution to the variables
shown to be more influential in the final results in the one and two-
way analyses. Variables included in the analysis were cost of IS
and FCM, indirect costs/hour, staff cost per hour, cost of infusion
devices and non-medical direct costs. These variables were tested
both according to a normal distribution and a uniform distribu-
tion, and performing 10,000 iterations.
The Ethics Committee of the Hospital of Sabadell reviewed and
approved the study. The study used retrospective data and neither
intervention nor genetic testing was performed. Patients’ data were
Figure 1. Iron dose according to the intravenous iron
indication. The size of the dots corresponds to the number of
patients receiving a given dose of intravenous iron. The most frequent
indication for intravenous iron was chronic blood losses associated to
liver disease. These patients also required the highest doses of
intravenous iron.
doi:10.1371/journal.pone.0045604.g001
Table 1. Indication, mean dose, transfusion requirements and mortality according to the indication of intravenous iron.
Indication
Patients
N (%)
Iron dose (mg)
mean ± SD
Patients transfused
n (%)
Blood Units
mean ± SD
Mortality
n (%)
Chronic liver disease 55 (49.5) 11786138 29 (53) 6.160.9 18 (32.7)
Inflammatory bowel disease 22 (19.8) 800684 3 (14) 3.360.3 2 (9)
Angiodysplasia 12 (10.8) 8336174 8 (67) 3.561.2 2 (16.7)
Other 22 (19.8) 8646106 6 (27) 461.1 1 (4.5)
doi:10.1371/journal.pone.0045604.t001
Intravenous Ferric Carboxymaltose vs. Iron Sucrose
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processed anonymously and were not available to third parties. As
a result, and in accordance with Spanish legislation, the Ethics
Committee did not require informed consent for the study. The
2007 Biomedical Research Act established the need for informed
consent and Ethics Committee approval for medical investigations
that either performed genetic testing or required invasive
procedures (Articles 1, 4.1 and 16 of the Law) but not for
retrospective studies. In fact, at present, there is no specific legal
regulation for the retrospective analysis of data obtained from
clinical records. These studies must, however, comply with the
1999 Personal Data Protection Act.
Results
A hundred and eleven patients (46 (41%) female, mean age
63.8618) were included in the previous clinical study. These 111
patients received 557 IS infusions, with a mean dose of
10336810 mg (range 200 to 5200 mg) of iron per patient. Major
indications for iron infusion were iron-deficient anemia associated
with liver cirrhosis, inflammatory bowel disease or gastrointestinal
angiodysplasia. Table 1 shows the number of patients, mean iron
dose, the number of patients requiring transfusion and the mean
transfusional requirements for the major indications for transfu-
sion. In general patients requiring intravenous iron had severe
baseline disease. Thirty-four (31%) were severely ill (category IV in
the American Society of Anesthesiologists – ASA – Physical Status
classification). Another 30 (27%) were ASA III, 26 (23%) ASA II
and only 21 (19%) did not have significant baseline disease (ASA
I). Seventy-one of the patients (64%) required admission. The
mean number of admissions during the study period was 4.2, a
third of them directly related to anemia. Twenty-three patients
(21%) died during the study period, all due to complications of
their baseline disease and most due to complications of their
chronic liver disease. Anemia was considered to contribute
significantly to death in seven patients. The doses of iron
according to the indication in the clinical retrospective data
collection are shown in figure 1. Major cost estimates are shown in
table 2.
As patients were assumed to receive iron infusion rounded to
the next 1000 mg dose when FCM was given, the calculated total
amount of iron given under base case assumptions was higher by
using FCM (135 g) than the amount given by using IS (111 g). The
estimated total cost of iron infusion per patient was J303.6 for IS
and J273.9 for FCM. So, the incremental cost of using IS was
J30 per patient. When the non-hospital direct costs were added to
the model, the difference in favour of FCM increased (J353.8 for
IS vs. J286.5 for FCM with an incremental cost of J67).
In one-way sensitivity analysis, IS and FCM prices and the day-
care unit personnel cost per hour were the most influential
Table 2. Costs, including upper and lower bounds used in the sensitivity and Monte Carlo analysis.
Cost (2009 J) Baseline Lower bound Upper bound
Cost iron sucrose 200 mg 23 5 23
Cost Ferric carboxymaltose 1000 mg 200 80 200
Cost infusion iron sucrose (1 h 15’) 47 35 60
Cost infusion Ferric carboxymaltose (45’) 35 28 42
Indirect cost/h 6 2 10
Staff cost/hour in day-care unit 18 12 24
Cost of infusion devices 7 5 10
Non-medical direct costs/session 10 2 20
Costs of drugs were obtained from the prices approved by the Spanish Agency for the Regulation of Drugs and Healthcare Products (15). All personnel and indirect
costs were obtained from the accounting department of the Hospital of Sabadell.
doi:10.1371/journal.pone.0045604.t002
Figure 2. One-way sensitivity analysis: Influence of the staff
cost/hour in the total cost per patient. Incremental cost of iron
sucrose over Ferric carboxymaltose increases as the staff costs increase.
doi:10.1371/journal.pone.0045604.g002
Figure 3. Two-way sensitivity analysis modifying costs of ferric
carboxymaltose and iron sucrose. The values in the table show
that the incremental cost (J) per treated patient was favoured ferric
carboxymaltose, unless if it cost more than J180 per 1000 mg and if
cost of iron sucrose decreased simultaneously below J10 per 200 mg.
doi:10.1371/journal.pone.0045604.g003
Intravenous Ferric Carboxymaltose vs. Iron Sucrose
PLOS ONE | www.plosone.org 3 September 2012 | Volume 7 | Issue 9 | e45604
variables in the model. Regarding personnel costs, the difference
in favour of FCM increased as the personnel cost increased
(Figure 2). However, even when decreasing the personnel costs by
50%, the analysis remained favourable to FCM. A two-way
sensitivity analysis changing at the same time the costs of IS and
FCM showed that, in the current scenario, the price of IS had to
be reduced to less than 9 euros to make the use of this drug less
expensive than the use of FCM (Figure 3). The analysis also
showed that a small decrease in the cost of FCM would lead to cost
savings independently of the IS cost. Similarly, the Monte Carlo
simulation favoured the use of FCM in 97.2% of all possible
scenarios, with a mean incremental cost of J87 for the use of IS
(Figure 4). Results were similar regardless of the assumed
distribution (uniform or normal) of the variables.
Discussion
The present cost minimization analysis evaluates the compar-
ative cost of using either IS or FCM for treating iron deficiency
anemia in a Gastrointestinal Diseases day-care unit. The study
suggests that under standard conditions the savings in costs
associated to the infusion and the day-care visits offset the higher
drug cost of FCM when compared with IS. The results of the
analysis were fairly stable and were reproduced in most of the
univariate and multivariate sensitivity analyses performed. It is
worth noting that these conclusions were obtained using the
Spanish National Health System personnel costs, which are
particularly low compared to those of other Western European
countries. The savings due to the reduced number of infusions can
be expected to be greater in situations with higher personnel costs.
Our results are mostly in accordance with the only similar study
published [16]. In that study, Bager et al. used three different
pharmacoeconomic approaches to compare the use of FCM and
IS for iron repletion, in patients with inflammatory bowel disease.
Both a cost-effectiveness analysis and a cost-benefit analysis
favoured FCM. However a budget impact analysis from a hospital
perspective favoured IS. By contrast, cost-minimization analysis in
our study, which is roughly equivalent to the budget impact
analysis in Bager’s manuscript, favoured FCM. There are two
main reasons for the difference. Firstly, drug costs in Denmark are
twice as high as those in Spain, decreasing the potential advantage
of FCM. Secondly, and probably more importantly, Bager’s study
presumably underestimated personnel costs as only nursing time
was taken into account. Although mean salaries in Spain are less
than half of those in Denmark [17], our estimated personnel costs
were higher than those reported by Bager et al. probably because
we included the cost of auxiliary personnel and the medical staff
support. Taking these two factors together, our analysis was largely
favourable to FCM. In addition, when non-hospital direct costs
were included, FCM was favoured even more.
The analysis is based on iron doses administered to real patients.
This is both a strength and a limitation of the study. It represents a
strength because the estimated costs will probably reflect the actual
situation in clinical practice. It can be seen as a limitation because
the analysis was performed in a particular patient population, most
of them of advanced age and suffering from a range of digestive
diseases leading to iron deficiency [14]. The costs could be
different in another setting such as, for example, monographic
inflammatory bowel disease units where patients are younger and
most of them are of working age, which increases work time losses
and therefore non-medical direct costs. In any case, the larger the
non-hospital direct costs, the more FCM is favoured.
A second limitation is that the analysis assumes equal efficacy
and safety for both drugs. Regarding efficacy, we reasonably
assumed that the efficacy of a given dose of iron would be similar
regardless of whether the dose was single or multiple. In fact, very
recent data from controled trials comparing IS and FCM in
patients with IBD suggest that FCM may be more efficacious than
IS. If confirmed, this superior efficacy could give additional
arguments suporting the clinical use of FCM [13].
It also seemed reasonable to analyze the strategy of adminis-
tering repeated 1000 mg iron doses to patients with chronic and
continuous iron losses that would require periodical iron infusions.
However, in order to model this approach we had to round the
iron dose to the next 1000 mg multiple. For this reason, the iron
dose administered in the FCM arm in the model was superior to
those administered in the IS model, increasing the drug costs in
the FCM groups. As the efficacy in both arms was assumed to be
similar, this may have introduced a slight bias in favour of the
200 mg dose IS infusion.
Regarding safety, early safety reviews showed a trend towards
increased mortality in patients receiving FCM, which led to a
request for further data from the FDA [18]. However, the trend
towards increased mortality did not correlate with an increase in
any other type of complication and was due to a wide range of
causes unlikely to be related to iron treatment [18]. In addition,
further studies and reviews have not found any risk increase to be
associated with FCM [19–22]. The most frequent cause of death (5
of 11 deaths in randomized trials) was cardiac disease. A recent
study in patients with cardiac failure found an improvement in
quality of life and functional status along with a trend towards
lower complications and mortality in patients treated with FCM
[23], thus essentially ruling out an increased risk of death or
complications attributable to FCM administration. Finally, our
study confirms that administering larger doses of iron in fewer
infusions reduces both hospital and societal costs. However, its
scope is limited to direct and indirect costs. Reducing outpatient
visits and infusions is expected to improve quality of life and has
the potential to reduce hospital admissions due to better
ambulatory control [23,24]. Measuring and adding these benefits
to the cost advantage shown in the present study could further
increase the estimated benefits of FCM [16].
Iron deficiency secondary to chronic diseases is increasing.
Indications for i.v. iron use are expanding as there is growing
evidence of reduced requirements for blood transfusions and
Figure 4. Monte Carlo simulation after 10,000 iterations. The
bars show the number of iterations that resulted in a given incremental
cost value. Values under 0 correspond to the simulations that favour the
use of Iron sucrose. As shown by the figure, the model favoured the use
of ferric carboxymaltose in 97% of the iterations.
doi:10.1371/journal.pone.0045604.g004
Intravenous Ferric Carboxymaltose vs. Iron Sucrose
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improved quality of life [23,24]. Intravenous iron administration
has already proven to be clinically effective in correcting iron
deficiency in a wide range of clinical settings, from inflammatory
bowel disease to heart failure [1,11,18,23–25]. Data on the
efficacy of intravenous iron in other settings are, however, scarce.
Previous studies by our group have shown an extensive use of i.v.
iron for indications such as chronic blood loss associated with liver
disease or angiodysplasia [14]. The efficacy of intravenous iron
(and specifically of, FCM in these indications remains to be
determined.
In conclusion, in this pharmacoeconomical model, ferric
carboxymaltose infusion was less costly than iron sucrose infusion
and appeared to reduce the costs of i.v. iron treatment in
outpatient day-care units.
Acknowledgments
We are indebted to Michael Maudsley for his help with the English.
Author Contributions
Conceived and designed the experiments: XC EG. Performed the
experiments: MR ML AF MM AD LM. Analyzed the data: XC DS
MR EG. Contributed reagents/materials/analysis tools: EG AV DS.
Wrote the paper: XC EG.
References
1. Schroder O, Mickisch O, Seidler U, de Weerth A, Dignass AU, et al. (2005)
Intravenous iron sucrose versus oral iron supplementation for the treatment of
iron deficiency anemia in patients with inflammatory bowel disease–a
randomized, controlled, open-label, multicenter study. Am J Gastroenterol
100: 2503–2509.
2. Gisbert JP, Gomollon F (2008) Common misconceptions in the diagnosis and
management of anemia in inflammatory bowel disease. Am J Gastroenterol 103:
1299–1307.
3. Johnson DW, Herzig KA, Gissane R, Campbell SB, Hawley CM, et al. (2001) A
prospective crossover trial comparing intermittent intravenous and continuous
oral iron supplements in peritoneal dialysis patients. Nephrol Dial Transplant
16: 1879–1884.
4. Kim YH, Chung HH, Kang SB, Kim SC, Kim YT (2009) Safety and usefulness
of intravenous iron sucrose in the management of preoperative anemia in
patients with menorrhagia: a phase IV, open-label, prospective, randomized
study. Acta Haematol 121: 37–41.
5. Seid MH, Derman RJ, Baker JB, Banach W, Goldberg C, et al. (2008) Ferric
carboxymaltose injection in the treatment of postpartum iron deficiency anemia:
a randomized controlled clinical trial. Am J Obstet Gynecol 199: 435–437.
6. Littlewood TJ, Alikhan R (2008) The use of intravenous iron in patients with
cancer-related anaemia. Br J Haematol; 141: 751–756.
7. Lindgren S, Wikman O, Befrits R, Blom H, Eriksson A, et al. (2009) Intravenous
iron sucrose is superior to oral iron sulphate for correcting anaemia and
restoring iron stores in IBD patients: A randomized, controlled, evaluator-blind,
multicentre study. Scand J Gastroenterol 44: 838–845.
8. Kulnigg S, Stoinov S, Simanenkov V, Dudar LV, Karnafel W, et al. (2008) A
novel intravenous iron formulation for treatment of anemia in inflammatory
bowel disease: the ferric carboxymaltose (FERINJECT) randomized controlled
trial. Am J Gastroenterol 103: 1182–1192.
9. Seril DN, Liao J, West AB, Yang GY (2006) High-iron diet: foe or feat in
ulcerative colitis and ulcerative colitis-associated carcinogenesis. J Clin Gastro-
enterol 40: 391–397.
10. Hayat A (2008) Safety issues with intravenous iron products in the management
of anemia in chronic kidney disease. Clin Med Res 6: 93–102.
11. Munoz M, Gomez-Ramirez S, Garcia-Erce JA (2009) Intravenous iron in
inflammatory bowel disease. World J Gastroenterol 5: 4666–4674.
12. Rubio C (2010) Ana´lisis farmacoecono´mico del tratamiento de la deficiencia de
hierro con hierro carboximaltosa (FerinjectH) en Espan˜a. PharmacoEconomics-
Spanish Research articles 7: 109–117.
13. Evstatiev R, Marteau P, Iqbal T, Khalif IL, Stein J, et al. (2011) FERGIcor, a
randomized controlled trial on ferric carboxymaltose for iron deficiency anemia
in inflammatory bowel disease. Gastroenterology 141: 846–853.
14. Dosal A, Calvet X, Moreno L, Lo´pez M, Figuerola A, et al. (2010) Use of
intravenous iron infusion in a gastroenterology day hospital: Indications, dosage
and adverse effects. Gastroenterol Hepatol 33: 479–483.
15. Consejo General de Colegios Oficiales de Farmace´uticos website. Available:
https://botplusweb.portalfarma.com/. Accessed 2010 Sep 15.
16. Bager P, Dahlerup JF (2010) The health care cost of intravenous iron treatment
in IBD patients depends on the economic evaluation perspective. J Crohns
Colitis 4: 427–430.
17. List of countries in Europe by monthly average wage. Available: http://en.
wikipedia.org/wiki/List_of_countries_in_Europe_by_monthly_average_wage.
Accessed 2012 May 8.
18. Lyseng-Williamson KA (2009) Ferric carboxymaltose: a review of its use in iron-
deficiency anaemia. Drugs 69: 739–759.
19. Qunibi WY (2010) The efficacy and safety of current intravenous iron
preparations for the management of iron-deficiency anaemia: a review.
Arzneimittelforschung 60: 399–412.
20. Kociol RD, Newby LK (2010) Ferric carboxymaltose improved symptoms and
quality of life in patients with chronic heart failure and iron deficiency. Ann
Intern Med 152: JC4–JC5.
21. Covic A, Mircescu G (2010) The safety and efficacy of intravenous ferric
carboxymaltose in anaemic patients undergoing haemodialysis: a multi-centre,
open-label, clinical study. Nephrol Dial Transplant 25: 2722–2730.
22. Grimmelt AC, Cohen CD, Fehr T, Serra AL, Wuethrich RP (2009) Safety and
tolerability of ferric carboxymaltose (FCM) for treatment of iron deficiency in
patients with chronic kidney disease and in kidney transplant recipients. Clin
Nephrol 71: 125–129.
23. Anker SD, Comin Colet J, Filippatos G, Willenheimer R, Dickstein K, et al.
(2009) Ferric carboxymaltose in patients with heart failure and iron deficiency.
N Engl J Med 361: 2436–2448.
24. Bailie GR (2010) Efficacy and safety of ferric carboxymaltose in correcting iron-
deficiency anemia: a review of randomized controlled trials across different
indications. Arzneimittelforschung 60: 386–98.
25. Bailie GR, Mason NA, Valaoras TG (2010) Safety and tolerability of
intravenous ferric carboxymaltose in patients with iron deficiency anemia.
Hemodial Int 14: 47–54.
Intravenous Ferric Carboxymaltose vs. Iron Sucrose
PLOS ONE | www.plosone.org 5 September 2012 | Volume 7 | Issue 9 | e45604
